Compositions and methods for treating age-related diabetes and related disorders
US-2018267059-A1 · Sep 20, 2018 · US
Compositions and methods for treating age-related diabetes and related disorders
US11428697B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11428697-B2 |
| Application number | US-201916702870-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 4, 2019 |
| Priority date | Jan 30, 2015 |
| Publication date | Aug 30, 2022 |
| Grant date | Aug 30, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of enhancing insulin sensitivity or reducing insulin resistance in a cell or tissue, the method comprising contacting an adipose cell or adipose tissue with an anti-ST2 antibody or an antigen binding fragment thereof, thereby increasing insulin-stimulated glucose uptake and enhancing insulin sensitivity or reducing insulin resistance in the adipose cell or adipose tissue. 2. The method of claim 1 , wherein the adipose cell or the adipose tissue is a visceral or subcutaneous adipose cell or tissue. 3. The method of claim 2 , further wherein one or both of visceral adipose tissue and subcutaneous adipose tissue adiposity is decreased. 4. The method of claim 1 , wherein the adipose cell or adipose tissue is from or within a subject having age-related insulin resistance. 5. The method of claim 4 , wherein the subject is at least 50 years old. 6. The method of claim 1 , wherein the adipose cell or adipose tissue is from or within a subject who is at risk of developing age-related insulin resistance. 7. The method of claim 6 , wherein the subject is at least 50 years old. 8. The method of claim 1 , wherein adipose tissue-resident regulatory T cell (fTreg) number is decreased in the adipose tissue.
Assignees
Inventors
Classifications
Prognosis of disease development · CPC title
Expression markers · CPC title
Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism · CPC title
Immunoassay; Biospecific binding assay; Materials therefor · CPC title
- G01N33/6869Primary
Interleukin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11428697B2 cover?
- The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
- Who is the assignee on this patent?
- Salk Inst For Biological Studi
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6869. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).